Roger Stupp

发表

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Walter J Curran, Deborah T Blumenthal, Mark R Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

Jacoline E. C. Bromberg, Michael Platten, Martin Bendszus, 2016 .

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Reto Meuli, Serge Leyvraz, Alessia Pica, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non steroidal anti‐inflammatory drugs and COX‐2 inhibitors as anti‐cancer therapeutics: hypes, hopes and reality

Curzio Rüegg, R. Stupp, C. Rüegg, 2003, Annals of medicine.

Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.

Damien C Weber, Akos Gulyban, R. Stupp, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Michael Weller, R. Mirimanoff, R. Stupp, 2006, The oncologist.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Michael Weller, Wolfgang Wick, Guido Reifenberger, 2012, Neuro-oncology.

A novel tool to analyze MRI recurrence patterns in glioblastoma.

Chris Rorden, Michael Platten, Hans-Otto Karnath, 2008, Neuro-oncology.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Martin J. van den Bent, R. Mirimanoff, R. Stupp, 2005, The New England journal of medicine.

Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.

Barbara Fisher, R. Mirimanoff, R. Stupp, 2004, European journal of cancer.

The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.

Patricia Werffeli, Khalil Zaman, Curzio Rüegg, 2003 .

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Alessia Pica, Bart Neyns, Michael Weller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia

Mauro Delorenzi, Curzio Rüegg, Eugenia Migliavacca, 2009, PloS one.

Lomustine and Bevacizumab in Progressive Glioblastoma

Martin Klein, Michael Platten, Martin Bendszus, 2017, The New England journal of medicine.

Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors.

Gerhard Christofori, Eveline Faes-van't Hull, Julien Laurent, 2011, Cancer research.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Eilon D. Kirson, Yoram Palti, Steven A. Toms, 2017 .

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Denis Lacombe, Johan M Kros, R. Stupp, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The dream and reality of histology agnostic cancer clinical trials

Denis Lacombe, Jan Bogaerts, Vassilis Golfinopoulos, 2014, Molecular oncology.

European perspective for effective cancer drug development

Sabine Tejpar, Denis Lacombe, Daniela Aust, 2014, Nature Reviews Clinical Oncology.

Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme

Maiwenn J Al, Ralph Crott, Carin A Uyl-de Groot, 2008, Cancer.

Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.

Damien C Weber, Akos Gulyban, Erik Roelofs, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Effect of computerisation on the quality and safety of chemotherapy prescription

Serge Leyvraz, Jean-Blaise Wasserfallen, R. Stupp, 2006, Quality and Safety in Health Care.

Anaplastic astrocytoma in adults.

Elena Mazza, Gemma Gatta, R. Stupp, 2007, Critical reviews in oncology/hematology.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma

Brigitta G. Baumert, Jaap C. Reijneveld, Andreas von Deimling, 2016, The Lancet. Oncology.

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Eytan Domany, Gad Getz, Mauro Delorenzi, 2003, Cancer research.

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Luca Regli, R. Stupp, M. Hegi, 2004, Clinical Cancer Research.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma

Eytan Domany, Mauro Delorenzi, Michael Weller, 2015, Genome Biology.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Didier Frappaz, R. Stupp, C. Marosi, 2012, The Lancet. Oncology.

NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

Charles Scott, Eric T. Wong, Santosh Kesari, 2014 .

ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA

Donald M. O'Rourke, John H. Sampson, Michael Lim, 2016 .

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Elizabeth Eisenhauer, Denis Lacombe, Michael Weller, 2008, The Lancet. Oncology.

Chemoradiotherapy in malignant glioma: standard of care and future directions.

Mark R Gilbert, Arnab Chakravarti, M. Gilbert, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.